[Featured Stock] SK Bioscience Rises on US Clinical Phase 3 Approval for Pneumococcal Vaccine

Up 4.24% Compared to Previous Close

SK Bioscience is showing strong performance in early trading on the 20th following news that it has received approval for the Phase 3 clinical trial plan of its 21-valent pneumococcal vaccine (GBP410) in the United States.

As of 10:09 AM on the same day, SK Bioscience is trading at 51,600 KRW, up 4.24% from the previous close.

On the 17th, SK Bioscience announced that it had received approval from the U.S. Food and Drug Administration (FDA) for the Phase 3 clinical trial plan of the 21-valent pneumococcal vaccine, which is being developed in collaboration with Sanofi. The global clinical trial, recruiting 7,700 participants worldwide, began dosing its first subject last month.

This content was produced with the assistance of AI translation services.